Workflow
Vor Bio Announces $175 Million Private Placement
VorVor(US:VOR) Globenewswireยท2025-06-25 20:50

Core Viewpoint - Vor Bio has announced a private placement in public equity financing (PIPE) expected to generate approximately $175 million in gross proceeds to advance its clinical pipeline and for general corporate purposes [1][3]. Group 1: Private Placement Details - Vor Bio will issue prefunded warrants to purchase a total of 700 million shares of common stock at a price of $0.25 per warrant [2]. - The PIPE includes participation from notable investors such as RA Capital Management, Mingxin Capital, Forbion, Venrock Healthcare Capital Partners, Caligan Partners, and NEXTBio [2]. - The expected closing date for the PIPE is June 27, 2025, pending customary closing conditions [3]. Group 2: Warrants and Stockholder Approval - The warrants have an exercise price of $0.0001 per share and will be exercisable upon stockholder approval for the issuance of the underlying shares [4]. - Vor Bio plans to hold a special stockholder meeting to seek approval for the issuance of the shares related to the warrants [4]. Group 3: Company Overview - Vor Bio is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, particularly through its novel dual-target fusion protein, telitacicept, which is in Phase 3 clinical development [7].